Maravai Lifesciences (MRVI) said Wednesday it expects to report 2024 revenue near the mid-point of its guidance range of $255 million to $265 million.
Analysts polled by FactSet expect $259.8 million.
The company said it will release its Q4 and full-year 2024 results after the market close on Feb. 25.
Maravai shares were falling 3.4% in recent after-hours trading.